<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Four pregnant women with antithrombin III congenital deficiency underwent <z:mp ids='MP_0005048'>thrombosis</z:mp> prophylaxis including oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> administered from the 16-18th week to the 36-37th week of pregnancy, subcutaneous <z:chebi fb="5" ids="28304">heparin</z:chebi> before the 16-18th week and after the 36-37th week, and a single infusion of AT III concentrate in the peripartum period in order to obtain a minimal level of 0.8 U/ml of AT III functional activity </plain></SENT>
<SENT sid="1" pm="."><plain>The level of circulating AT III after the concentrate infusion needs to be evaluated by functional methods, because of a consistent amount in the concentrates of inactive AT III immunoreactive material </plain></SENT>
<SENT sid="2" pm="."><plain>No thrombotic or haemorrhagic complication occurred after starting prophylaxis in any woman either in any newborn </plain></SENT>
</text></document>